Spots Global Cancer Trial Database for neuroendocrine carcinomas
Every month we try and update this database with for neuroendocrine carcinomas cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas | NCT04122911 | Neuroendocrine ... | Temozolomide | 18 Years - | National Cancer Institute, Naples | |
| Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer | NCT02820857 | Neuroendocrine ... | Folfiri-bevaciz... Folfiri | 18 Years - | Hospices Civils de Lyon | |
| Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors | NCT01203306 | Neuroendocrine ... | bevacizumab + o... | 18 Years - 80 Years | University of Turin, Italy | |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | NCT05337735 | Microsatellite ... Peritoneal Meso... Extrapulmonary ... Neuroendocrine ... Cervical Carcin... Hodgkin's Lymph... Pleural Mesothe... Small Cell Lung... | XmAb20717 | 18 Years - | M.D. Anderson Cancer Center | |
| Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin | NCT02695459 | Neuroendocrine ... | cisplatinum and... | 18 Years - | The Netherlands Cancer Institute | |
| Octreotide LAR as Maintenance Treatment for Patients With NEC | NCT02409849 | Gastro-entero-p... Esophageal Neur... | Octreotide lar | - | Peking University | |
| Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients | NCT02457273 | Neuroendocrine ... | TLC 388 | 20 Years - | National Health Research Institutes, Taiwan | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | NCT05599984 | Advanced Solid ... | ABBV-706 Cisplatin Budigalimab Carboplatin | 18 Years - | AbbVie | |
| Octreotide LAR as Maintenance Treatment for Patients With NEC | NCT02409849 | Gastro-entero-p... Esophageal Neur... | Octreotide lar | - | Peking University | |
| Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET) | NCT04720391 | Bone Metastases Neuroendocrine ... | - | European Institute of Oncology | ||
| Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients | NCT02457273 | Neuroendocrine ... | TLC 388 | 20 Years - | National Health Research Institutes, Taiwan | |
| Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors | NCT01203306 | Neuroendocrine ... | bevacizumab + o... | 18 Years - 80 Years | University of Turin, Italy |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
